

Full Portfolio Holdings* as of March 31, 2024

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
BASE CURRENCY					
US DOLLAR			1,623,228	1,623,228	1.13%
COMMON STOCKS					
Eli Lilly & Co.			20,140	15,668,114	10.95%
UnitedHealth Group, Inc.			19,118	9,457,675	6.61%
Merck & Co., Inc.			69,584	9,181,609	6.42%
Danaher Corp.			21,408	5,346,006	3.74%
Stryker Corp.			11,277	4,035,700	2.82%
Boston Scientific Corp.			58,809	4,027,828	2.82%
HCA Healthcare, Inc.			10,833	3,613,130	2.53%
Thermo Fisher Scientific, Inc.			6,125	3,559,911	2.49%
AbbVie, Inc.			18,845	3,431,675	2.40%
Vertex Pharmaceuticals, Inc.			7,664	3,203,629	2.24%
Centene Corp.			38,547	3,025,169	2.11%
Cencora, Inc.			12,346	2,999,955	2.10%
Abbott Laboratories			24,981	2,839,340	1.98%
Edwards Lifesciences Corp.			28,582	2,731,296	1.91%
Zoetis, Inc.			15,887	2,688,239	1.88%
AstraZeneca PLC			36,421	2,467,523	1.72%
Dexcom, Inc.			17,602	2,441,397	1.71%
Regeneron Pharmaceuticals, Inc.			2,472	2,379,275	1.66%
Molina Healthcare, Inc.			5,455	2,241,078	1.57%
Agilent Technologies, Inc.			14,932	2,172,755	1.52%
Humana, Inc.			5,996	2,078,933	1.45%
Shockwave Medical, Inc.			6,004	1,955,083	1.37%
Acadia Healthcare Co., Inc.			24,301	1,925,125	1.35%
ICON PLC			5,727	1,923,986	1.34%
Daiichi Sankyo Co. Ltd.			59,735	1,900,700	1.33%
Laboratory Corp. of America Holdings			6,082	1,328,674	0.93%
Illumina, Inc.			8,722	1,197,705	0.84%
Hologic, Inc.			14,240	1,110,150	0.78%
Encompass Health Corp.			13,067	1,079,073	0.75%
Pfizer, Inc.			38,467	1,067,459	0.75%
Argenx SE			2,632	1,036,271	0.72%
Waters Corp.			2,949	1,015,134	0.71%
GSK PLC			46,993	1,008,957	0.71%
Chugai Pharmaceutical Co. Ltd.			26,100	997,422	0.70%
Insulet Corp.			5,770	988,978	0.69%
Option Care Health, Inc.			29,290	982,387	0.69%
Novartis AG			9,744	943,788	0.66%
Galderma Group AG			12,515	879,110	0.61%
UCB SA			7,120	878,942	0.61%
Eisai Co. Ltd.			20,809	857,097	0.60%

Full Portfolio Holdings* as of March 31, 2024

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Repligen Corp.			4,590	844,193	0.59%
Biogen, Inc.			3,769	812,709	0.57%
Evolent Health, Inc.			24,660	808,601	0.57%
Addus HomeCare Corp.			7,534	778,564	0.54%
Elanco Animal Health, Inc.			45,874	746,829	0.52%
United Therapeutics Corp.			3,231	742,225	0.52%
Otsuka Holdings Co. Ltd.			17,500	726,920	0.51%
Qiagen NV			16,508	709,679	0.50%
Teleflex, Inc.			2,977	673,308	0.47%
Surgery Partners, Inc.			22,421	668,818	0.47%
Alnylam Pharmaceuticals, Inc.			4,432	662,362	0.46%
agilon health, Inc.			105,937	646,216	0.45%
Exact Sciences Corp.			9,220	636,733	0.45%
Ascendis Pharma AS			4,209	636,275	0.44%
REVOLUTION Medicines, Inc.			19,460	627,196	0.44%
Celldex Therapeutics, Inc.			14,647	614,735	0.43%
Immunocore Holdings PLC			9,207	598,455	0.42%
Crinetics Pharmaceuticals, Inc.			12,660	592,615	0.41%
Apellis Pharmaceuticals, Inc.			10,027	589,387	0.41%
Cytokinetics, Inc.			8,300	581,913	0.41%
Sarepta Therapeutics, Inc.			4,248	549,946	0.38%
Amgen, Inc.			1,870	531,678	0.37%
Privia Health Group, Inc.			27,050	529,910	0.37%
Tecan Group AG			1,268	525,370	0.37%
Structure Therapeutics, Inc.			12,185	522,249	0.37%
DiaSorin SpA			5,296	511,089	0.36%
Merus NV			10,840	488,125	0.34%
Alkermes PLC			17,684	478,706	0.33%
Vaxcyte, Inc.			6,990	477,487	0.33%
Syndax Pharmaceuticals, Inc.			19,231	457,698	0.32%
Rocket Pharmaceuticals, Inc.			16,735	450,841	0.32%
Bio-Techne Corp.			6,336	445,991	0.31%
Genmab AS			1,472	441,348	0.31%
Inari Medical, Inc.			9,031	433,307	0.30%
Ultragenyx Pharmaceutical, Inc.			9,251	431,929	0.30%
Moderna, Inc.			3,856	410,895	0.29%
Blueprint Medicines Corp.			4,317	409,511	0.29%
Veracyte, Inc.			18,294	405,395	0.28%
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.			20,200	400,987	0.28%
Xenon Pharmaceuticals, Inc.			9,265	398,858	0.28%
Gilead Sciences, Inc.			5,320	389,690	0.27%
Verona Pharma PLC			23,038	370,681	0.26%
Bridgebio Pharma, Inc.			10,995	339,965	0.24%
Immatics NV			30,125	316,614	0.22%
Soleno Therapeutics, Inc.			7,290	312,012	0.22%

Full Portfolio Holdings* as of March 31, 2024

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Longboard Pharmaceuticals, Inc.			14,280	308,448	0.22%
Autolus Therapeutics PLC			47,398	302,399	0.21%
Legend Biotech Corp.			5,268	295,482	0.21%
Akero Therapeutics, Inc.			11,545	291,627	0.20%
Genus PLC			12,836	285,518	0.20%
PTC Therapeutics, Inc.			8,468	246,334	0.17%
Inspire Medical Systems, Inc.			1,130	242,713	0.17%
Zai Lab Ltd.			11,383	182,356	0.13%
Morphic Holding, Inc.			4,712	165,862	0.12%
Prothena Corp. PLC			5,721	141,709	0.10%
Smith & Nephew PLC			6,994	87,558	0.06%
Contra Abiomed, Inc.			885	903	0.00%
FOREIGN CURRENCY					
BRAZILIAN REAL			226,512	45,163	0.03%
JAPANESE YEN			2,120,401	14,007	0.01%
POUND STERLING			1,346	1,699	0.00%
SWISS FRANC			35	39	0.00%
EURO CURRENCY			19	21	0.00%
DANISH KRONE			34	5	0.00%
HONG KONG DOLLAR			5	0.58	0.00%
SHORT-TERM INVESTMENTS					
Fixed Income Clearing Corp.		4/1/2024	418,476	418,476	0.29%
DERIVATIVES - FOREIGN CURRENCY EXCHANGE CONTRACTS (SPOT)					
SWISS FRANC		4/2/2024	51,130	234	0.00%
EURO CURRENCY		4/2/2024	(12,042)	40	0.00%
DANISH KRONE		4/3/2024	(29,140)	15	0.00%
POUND STERLING		4/2/2024	(10,379)	10	0.00%
JAPANESE YEN		4/1/2024	(2,120,400)	1	0.00%
POUND STERLING		4/2/2024	(1,346)	0	0.00%
BRAZILIAN REAL		4/2/2024	(1,167,897)	(5)	0.00%
SWISS FRANC		4/3/2024	45,257	(9)	0.00%
JAPANESE YEN		4/1/2024	(6,562,258)	(19)	0.00%
SWISS FRANC		4/2/2024	(4,433)	(20)	0.00%
TOTAL INVESTMENTS				142,048,086	99.29%
OTHER ASSETS LESS LIABILITIES				1,011,570	0.71%
TOTAL NET ASSETS				143,059,656	100.00%

Full Portfolio Holdings* as of March 31, 2024

* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on www.hartfordfunds.com for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual report to shareholders filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

227833 03/22